NASDAQ · MPLT
MapLight Therapeutics, Inc.
$7.72-$0.26 (-3.26%)
MapLight Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.91% below the high.
Loading market information…
NASDAQ · ERNA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ernexa Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Ernexa Therapeutics Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -$3.84. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ernexa Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$48.00-28.0% vs estimate |
| $1.00K |
| Q3 2024 | Nov 12, 2024 | -$0.74-207.33% vs estimate | $487.00K |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.72-$0.26 (-3.26%)
MapLight Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.91% below the high.
$11.08+$0.01 (+0.09%)
ProMIS Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.56% below the high.
$1.23-$0.01 (-0.81%)
Dogwood Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.54% below the high.
$0.29+$0.03 (+11.36%)
AEON Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.72% below the high.
$8.72-$0.03 (-0.29%)
Moleculin Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.23% below the high.
$0.03-$0.00 (-9.41%)
Adaptimmune Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 92.73% below the high.
$1.85+$0.23 (+14.2%)
BiomX Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.5% below the high.
$0.12$0.00 (0.0%)
OSR Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.17% below the high.
